Central Obesity and Cancer Prevention for Chinese American Women

November 28, 2023 updated by: San Francisco State University
This project examines the feasibility of a smartphone-based intervention to reduce obesity and breast cancer risk among Chinese American women in San Francisco. The proposed intervention is to use the mobile application and an activity tracker device to promote a healthier lifestyle and physical activity. Ultimately, the findings will advance the NIH mission of enhancing health promotion and disease prevention.

Study Overview

Status

Completed

Detailed Description

Cancer is the leading cause of death in women in the United States (US). Chinese Americans are the largest ethnic group among Asian Americans. Although the incidence of breast cancer, the most common cancer in women, has decreased among other U.S racial groups over the last 15 years, Chinese American women in California have experienced a significant increase of incidence of 1.1% from 1998 to 2013. Studies have found that assimilation stress and obesity are associated with increased risk for breast cancer in Chinese American women. There are no existing interventions targeted at breast cancer prevention among premenopausal mothers with abdominal obesity. Interventions tailored to an individual's cultural, lifestyle and social support system are needed to reduce obesity and breast cancer risk. A smartphone-based intervention provides a promising platform for obesity and cancer prevention. The overall goal of this project is to test the feasibility of an obesity and breast cancer prevention intervention among Chinese American women in San Francisco. The investigators will adapt the Healthy Mothers Healthy Children: Technology-Based Intervention to Prevent Obesity to reduce obesity and breast cancer risk in premenopausal women with abdominal obesity who have dependent children in San Francisco. The proposed intervention ("Smartphone-Based Cancer and Obesity Prevention Program for Chinese Women: SCOPP-CW) includes 12 weekly educational modules and six bi-weekly tailored messages delivered via WeChat, a popular private communication app used by Chinese and Chinese Americans. The investigators propose to conduct a pilot randomized control study (RCT) to assess the short-term efficacy of SCOPP-CW on abdominal obesity, breast cancer knowledge and attitudes, weight-related behaviors (food intake and physical activity), and metabolic risk (blood pressure, lipid profile, hemoglobin A1c), which are associated with breast cancer. Thus the investigators propose the following aims: (1) Aim 1: To estimate the preliminary efficacy of the SCOPP-CW intervention on the primary outcomes (i.e. waist circumference and breast cancer knowledge and attitudes) and secondary outcomes (i.e. body mass index, self-efficacy, food intake, physical activity at baseline, 3 months, and 6 months, and metabolic risk [blood pressure, hemoglobin A1C, and lipid panel]) at baseline and 6 months.

Aim 2: To assess feasibility by understanding participants' acceptance, barriers to adherence and recommendations for intervention using focus group interviews. The investigators anticipate that this intervention will have a significant impact on breast cancer prevention. The investigators plan to use the proposed pilot study's findings to conduct a larger scale randomized trial (R01) to test the long-term efficacy of the intervention.

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Fang-yu Chou, PhD
  • Phone Number: 415-3386853
  • Email: fchou@sfsu.edu

Study Contact Backup

Study Locations

    • California
      • San Francisco, California, United States, 94132
        • San Francisco State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • be female
  • be at least 18 years old
  • have a waist circumference great than 80 cm
  • own a smartphone
  • be able to read Chinese and speak Mandarin
  • be premenopausal
  • have a child between the age of 1 and 18 years old.

Exclusion Criteria:

  • are pregnant
  • gave birth less than 12 months prior to enrollment date
  • have a history of breast cancer
  • have an acute or life-threatening disease (e.g., renal failure).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
  1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns.
  2. 12 weekly SCOPP-CW educational modules delivered via WeChat.
  3. 6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences
The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
Active Comparator: Control
  1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns.
  2. 12 weekly non-tailored educational modules on general health topics delivered via WeChat.
This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
waist circumference
Time Frame: Change from baseline waist measurement at 3 months and 6 months
waist measured in centimeters by NIH waist circumference measurement protocol
Change from baseline waist measurement at 3 months and 6 months
breast cancer knowledge and attitudes
Time Frame: Change from baseline breast cancer screening knowledge score at 3 months and 6 months
13-item self-report questionnaire measuring knowledge, attitude, and practice of breast cancer screening
Change from baseline breast cancer screening knowledge score at 3 months and 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
body mass index
Time Frame: change from baseline BMI at 3 months and 6 months
Weight and height (weight [kg]/height [m])
change from baseline BMI at 3 months and 6 months
self-efficacy
Time Frame: Change from baseline self-efficacy questionnaire score at 3 months and 6 months
28-item self-report survey measuring self-efficacy on nutrition, stress management, physical activity
Change from baseline self-efficacy questionnaire score at 3 months and 6 months
food intake
Time Frame: Change from baseline food frequency at 3 months and 6 months
Chinese food frequency questionnaire (FFQ) includes 118 food items
Change from baseline food frequency at 3 months and 6 months
physical activity
Time Frame: Change from baseline daily physical activity at 3 months and 6 months
Daily tracking 10 hours awake time with a Fitbit device
Change from baseline daily physical activity at 3 months and 6 months
blood pressure
Time Frame: Change from baseline blood pressure at 3 months and 6 months
Systolic and diastolic blood pressure measured in mmHg
Change from baseline blood pressure at 3 months and 6 months
Hemoglobin A1C
Time Frame: Change from baseline hemoglobin A1C at 6 months
Glycated hemoglobin to measure average level of blood sugar
Change from baseline hemoglobin A1C at 6 months
Lipid panel
Time Frame: Change from baseline lipid panel at 6 months
A blood test that measures the level of different types of fat (lipid molecules) in the blood
Change from baseline lipid panel at 6 months
C-reactive protein
Time Frame: Change from baseline lipid panel at 6 months
A blood test that measure the presence of inflammation in the body
Change from baseline lipid panel at 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of uses of the tracking app
Time Frame: at 6 months
Weekly number of uses of the tracking app
at 6 months
Frequency of accessing the 12 educational modules
Time Frame: at 6 months
Weekly number of accessing the educational modules
at 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jyu-Lin Chen, PhD, University of California, San Francisco
  • Principal Investigator: Fang-yu Chou, PhD, San Francisco State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2019

Primary Completion (Actual)

August 31, 2021

Study Completion (Actual)

August 31, 2021

Study Registration Dates

First Submitted

January 9, 2019

First Submitted That Met QC Criteria

January 14, 2019

First Posted (Actual)

January 15, 2019

Study Record Updates

Last Update Posted (Actual)

November 30, 2023

Last Update Submitted That Met QC Criteria

November 28, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 20429001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Abdominal

Clinical Trials on SCOPP-CW

3
Subscribe